GreenSpace Labs is a pioneering brand dedicated to the research and development of cannabinoid-based therapeutics. Recognizing the lack of clinical evidence and standardization in this field, GreenSpace Labs was established to provide science-backed solutions for a wide range of diseases using cannabis, CBD, and other cannabinoids. While there have been remarkable claims about the efficacy of these substances, most lack scientific validation.

With a science-driven approach, GreenSpace Labs aims to change that. Currently, the Food and Drug Administration (FDA) has only approved one cannabinoid-based treatment, a CBD-containing oil for pediatric epilepsy. However, GreenSpace Labs is actively collaborating with the FDA to introduce other treatments to the market.

They are committed to following the appropriate regulatory pathways and conducting necessary clinical studies. GreenSpace Labs works closely with various partners including investment bankers, Umergence Formulation Partners, Bioduro, Intellectual Property Plant and Planet, and General Counsel Novus | GC. Through their dedication to research, GreenSpace Labs strives to bring reliable healthcare solutions using cannabinoids to the forefront